We undertook an exploratory post hoc analysis of data from a 6-month clinical trial of 303 patients randomised to combination budesonide/formoterol inhaler according to a Single combination inhaler as Maintenance And Reliever Therapy regimen ( ` SMART ' ) or fixed-dose budesonide/formoterol with salbutamol as reliever ( ` Standard ' ) .